Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

To estimate the prevalence of inadequate pain relief (IPR) among patients with symptomatic knee OA prescribed analgesic therapy and to characterize patients with IPR.Patients ≥50 years old with physician-diagnosed knee OA who had taken topical or oral pain medication for at least 14 days were recruited for this prospective non-interventional study in six European countries. Pain and function were assessed using the Brief Pain Inventory (BPI) and the WOMAC; quality of life (QoL) was assessed using the 12-item short form. IPR was defined as an average pain score of >4 out of 10 on BPI question 5.Of 1187 patients enrolled, 68% were female and the mean age was 68 years (s.d. 9); 639 (54%) met the definition of IPR. Patient responses for the BPI average pain question were well correlated with responses on the WOMAC pain subscale (Spearman r = 0.64, P < 0.001). In multivariate logistic regression, patients with IPR had greater odds of being female [adjusted odds ratio (adjOR) 1.90 (95% CI 1.46, 2.48)] and having OA in both knees [adjOR 1.48 (95% CI 1.15, 1.90)], higher BMI, longer OA duration, depression or diabetes. Patients with IPR (vs non-IPR) were more likely to have worse QoL, greater function loss and greater pain interference.IPR is common among patients with knee OA requiring analgesics and is associated with large functional loss and impaired QoL. Patients at particular risk of IPR, as characterized in this study, may require greater attention towards their analgesic treatment options.https://clinicaltrials.gov/ (NCT01294696).

Type

Journal article

Journal

Rheumatology (Oxford, England)

Publication Date

02/2015

Volume

54

Pages

270 - 277

Addresses

Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK, Clinical Development, MRL, Merck & Co., Kenilworth, Global Health Outcomes, Merck & Co., Whitehouse Station, MedData Analytics, East Brunswick, NJ, College of Pharmacy, St Johns University, Queens, NY, USA, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Centre for Health Economics, Swansea University, Swansea, UK, Cochin Hospital, Rehabilitation Department, University of Paris, Paris, France, Department of Rheumatology and Clinical Immunology, University of Twente, Enschede, The Netherlands and Pain Research & Nuffield Department of Anaesthetics, Oxford University, Oxford, UK.

Keywords

Humans, Osteoarthritis, Knee, Analgesics, Pain Measurement, Treatment Outcome, Administration, Oral, Administration, Cutaneous, Prospective Studies, Quality of Life, Aged, Patient Satisfaction, Female, Male, Musculoskeletal Pain